Circulating KIM-1 and survival outcomes in renal cell carcinoma: A systematic review and meta-analysis [0.03%]
肾细胞癌中循环KIM-1与生存结果的相关性:系统评价和荟萃分析
Jiafu Lu,Bo Luo,Chao Xue et al.
Jiafu Lu et al.
Background: Renal cell carcinoma (RCC) exhibits substantial clinical heterogeneity, and conventional clinicopathological models have limited ability to provide precise individualized risk stratification. Circulating kidne...
Deep learning approaches for predicting response to neoadjuvant chemotherapy in muscle invasive bladder cancer: A systematic review [0.03%]
深度学习在肌侵袭性膀胱癌新辅助化疗反应预测中的应用:系统综述
Mohammad Reza Nowroozi,Mohammad Hamidi Madani,Amirreza Farzin et al.
Mohammad Reza Nowroozi et al.
Neoadjuvant chemotherapy (NAC) followed by radical cystectomy is the standard of care for muscle-invasive bladder cancer (MIBC), yet treatment response is highly variable and current clinical predictors are inadequate. Deep learning (DL) of...
Lutetium-177-PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer: A systematic review of efficacy, safety, and combination strategies [0.03%]
镥-177-PSMA放射配体治疗转移性激素敏感型前列腺癌:疗效、安全性和联合策略的系统评价
Joseph McGrath,Robert Willis,Sudharshanan Balaji et al.
Joseph McGrath et al.
Lutetium-177-labeled prostate-specific membrane antigen radioligand therapy (¹⁷⁷Lu-PSMA-RLT) emerged as a novel treatment for metastatic castration-resistant prostate cancer (mCRPC) following FDA approval in 2022. Its role in metastatic ...
Real-world safety and effectiveness of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: A multicenter Japanese cohort study [0.03%]
恩沙鲁单抗联合派姆单抗治疗局部晚期或转移性尿路上皮癌的真实世界安全性和有效性:一项多中心日本队列研究
Takafumi Yanagisawa,Kosuke Iwatani,Fumihiko Urabe et al.
Takafumi Yanagisawa et al.
Background: Enfortumab vedotin plus pembrolizumab (EVP) has emerged as a standard first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). However, large-scale real-world data in Japanese pat...
Emerging antibody-drug conjugates in metastatic castration-resistant prostate cancer [0.03%]
用于转移性去势抵抗性前列腺癌的新兴抗体-药物偶联物
Charles B Nguyen,Zachery R Reichert
Charles B Nguyen
Despite recent advances in therapies, metastatic castration-resistant prostate cancer (mCRPC) remains incurable with poor prognosis in which novel, more effective treatments are urgently needed. Antibody-drug conjugates (ADCs) are a novel c...
Post-treatment diffusion MRI-derived apparent diffusion coefficient as a biomarker of response and prognosis following definitive radiotherapy for prostate cancer: Impact of focal dose escalation on ADC dynamics [0.03%]
根治性放疗后前列腺癌患者表观扩散系数作为治疗反应和预后的生物标志物:焦点剂量升级对ADC动力学的影响
Cem Onal,Gurcan Erbay,Ozan Cem Guler et al.
Cem Onal et al.
Background: Diffusion-weighted magnetic resonance imaging (MRI)-derived apparent diffusion coefficient (ADC) has been investigated as a biomarker in prostate cancer, yet its prognostic relevance after definitive radiother...
Retraction notice to "Effects of the T-786C, G894T and Intron 4 VNTR (4a/b) Polymorphisms of the Endothelial Nitric Oxide Synthase Gene on the Risk of Prostate Cancer" [Urologic Oncology: Seminars and Original Investigations 31 (2013) 1132-1140] [0.03%]
《的撤稿声明》[乌罗肿瘤学:论文和原创研究 31 (2013) 1132-1140]
Mohammad Reza Safarinejad,Shiva Safarinejad,Nayyer Shafiei et al.
Mohammad Reza Safarinejad et al.
Clinicopathological features and prognosis of plasmacytoid urothelial carcinoma of the bladder: A retrospective analysis of 36 cases [0.03%]
12例膀胱浆细胞样尿路上皮癌的临床病理特征及预后分析
Xueping Liu,Kui Fu,Lixia Xiong et al.
Xueping Liu et al.
Objective: To investigate the clinicopathological features, immunophenotype, treatment response, and prognosis of plasmacytoid urothelial carcinoma (PUC) of the bladder, and to provide evidence for clinical management. ...
Network meta-analysis of immune checkpoint inhibitors in BCG-naïve, high-risk non-muscle-invasive bladder cancer [0.03%]
免疫检查点抑制剂治疗卡介苗初治高危非肌层浸润性膀胱癌的网状meta分析
Joseph McGrath,Indraneel Banerjee,Yudai Ishiyama et al.
Joseph McGrath et al.
Purpose: Bacillus Calmette-Guérin (BCG) remains the standard first-line therapy for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC), yet recurrence and progression remain clinically significant. Multiple ...
Efficacy and safety of first-line immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients on hemodialysis [0.03%]
免疫检查点抑制剂联合治疗终末期肾癌透析患者的有效性和安全性
Hidetsugu Takahashi,Wataru Fukuokaya,Takafumi Yanagisawa et al.
Hidetsugu Takahashi et al.
Background: Immune checkpoint inhibitor (ICI)-based combination therapy (ICI plus ICI [IO-IO] or ICI plus tyrosine kinase inhibitor [IO-TKI]) is the standard first-line treatment for metastatic renal cell carcinoma (mRCC)...